Optum RX says US FTC insulin suit’s ‘materially different’ facts merit split hearings
MLex Summary: Optum Rx told a US Federal Trade Commission administrative law judge that "materially different" factual allegations merit separate proceedings in an agency suit over insulin prices brought against Optum,...To view the full article, register now.
Already a subscriber? Click here to view full article